Key result
Low-dose urokinase increased CTPA-confirmed absorption and reduced short-term dyspnea at discharge (27.59% vs. 52.00%) compared to anticoagulant therapy, without significantly affecting mortality or bleeding risk.
Why the study?
Patients with intermediate-high-risk pulmonary embolism have high risk of adverse outcomes, but the role of thrombolytic therapy in this setting remains controversial.
Does low-dose urokinase improve thrombus absorption, dyspnea, and mortality in patients with acute intermediate-high-risk pulmonary embolism compared to anticoagulation alone?
Population
81 consecutive patients with intermediate-high-risk PE from two centers
Comparison
Low-dose urokinase vs low-molecular-weight heparin
Design
Two-center retrospective cohort study
Authors
Loading...
Low-dose UK may improve absorption and dyspnea in intermediate-high-risk PE without raising bleeding or mortality; leaves open confirmation via randomized trials.
Cohort (n=81)
Yes
Does low-dose urokinase improve thrombus absorption, dyspnea, and mortality in patients with acute intermediate-high-risk pulmonary embolism compared to anticoagulation alone?
Absolute Event Rate: 6.45% vs 0%
p-value: p=0.144
Low-dose urokinase may safely accelerate thrombus resolution and relieve dyspnea in intermediate-high-risk pulmonary embolism without increasing bleeding risk.
Weng et al. (2021) conducted a cohort in Acute intermediate-high-risk pulmonary embolism (n=81). Low-dose urokinase (UK) combined with low-molecular-weight heparin (LMWH) vs. Low-molecular-weight heparin (LMWH) alone was evaluated on In-hospital mortality (p=0.144). Low-dose urokinase increased CTPA-confirmed absorption and reduced short-term dyspnea at discharge (27.59% vs. 52.00%) compared to anticoagulant therapy, without significantly affecting mortality or bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: